Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A. Cavazzoni A, et al. Among authors: barocelli e. Mol Cancer. 2012 Dec 12;11:91. doi: 10.1186/1476-4598-11-91. Mol Cancer. 2012. PMID: 23234355 Free PMC article.
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity.
Bertoni S, Ballabeni V, Flammini L, Saccani F, Domenichini G, Morini G, Comini M, Rivara M, Barocelli E. Bertoni S, et al. Among authors: barocelli e. Naunyn Schmiedebergs Arch Pharmacol. 2008 Sep;378(3):335-43. doi: 10.1007/s00210-008-0299-2. Epub 2008 May 22. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18496672
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S, Madeddu D, Tiseo M, Vivo V, Galetti M, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Falco A, Gervasi A, Lagrasta CA, Naldi N, Barocelli E, Ardizzoni A, Quaini F, Petronini PG, Alfieri R. La Monica S, et al. Among authors: barocelli e. J Thorac Oncol. 2016 Jul;11(7):1051-63. doi: 10.1016/j.jtho.2016.03.006. Epub 2016 Mar 19. J Thorac Oncol. 2016. PMID: 27006151 Free article.
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
Fumarola C, Cretella D, La Monica S, Bonelli MA, Alfieri R, Caffarra C, Quaini F, Madeddu D, Falco A, Cavazzoni A, Digiacomo G, Mazzaschi G, Vivo V, Barocelli E, Tiseo M, Petronini PG, Ardizzoni A. Fumarola C, et al. Among authors: barocelli e. Oncotarget. 2017 Jul 17;8(54):91841-91859. doi: 10.18632/oncotarget.19279. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190880 Free PMC article.
170 results